Literature DB >> 29714631

Peroxisome Proliferator-activated Receptor γ and Mitochondria: Drivers or Passengers on the Road to Pulmonary Hypertension?

Kurt R Stenmark1,2, Rubin M Tuder2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29714631      PMCID： PMC5946332          DOI： 10.1165/rcmb.2017-0318ED

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN： 1044-1549            Impact factor:   6.914


× No keyword cloud information.
  26 in total

1.  Modern age pathology of pulmonary arterial hypertension.

Authors:  Elvira Stacher; Brian B Graham; James M Hunt; Aneta Gandjeva; Steve D Groshong; Vallerie V McLaughlin; Marsha Jessup; William E Grizzle; Michaela A Aldred; Carlyne D Cool; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

Review 2.  PPARgamma in immunity and inflammation: cell types and diseases.

Authors:  Lajos Széles; Dániel Töröcsik; László Nagy
Journal:  Biochim Biophys Acta       Date:  2007-02-24

Review 3.  Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha.

Authors:  P Puigserver
Journal:  Int J Obes (Lond)       Date:  2005-03       Impact factor: 5.095

4.  Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.

Authors:  Travis S Hughes; Michael J Chalmers; Scott Novick; Dana S Kuruvilla; Mi Ra Chang; Theodore M Kamenecka; Mark Rance; Bruce A Johnson; Thomas P Burris; Patrick R Griffin; Douglas J Kojetin
Journal:  Structure       Date:  2012-01-11       Impact factor: 5.006

Review 5.  PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function.

Authors:  Istvan Szatmari; Eva Rajnavolgyi; Laszlo Nagy
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

6.  Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

Authors:  Julie St-Pierre; Stavit Drori; Marc Uldry; Jessica M Silvaggi; James Rhee; Sibylle Jäger; Christoph Handschin; Kangni Zheng; Jiandie Lin; Wenli Yang; David K Simon; Robert Bachoo; Bruce M Spiegelman
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

7.  Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension.

Authors:  Rasa Tamosiuniene; Wen Tian; Gundeep Dhillon; Lijuan Wang; Yon K Sung; Lajos Gera; Andrew J Patterson; Rani Agrawal; Marlene Rabinovitch; Kelly Ambler; Carlin S Long; Norbert F Voelkel; Mark R Nicolls
Journal:  Circ Res       Date:  2011-08-25       Impact factor: 17.367

8.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

Authors:  Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-22       Impact factor: 5.464

Review 9.  Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene.

Authors:  R M Tuder; M E Yeager; M Geraci; H A Golpon; N F Voelkel
Journal:  Eur Respir J       Date:  2001-06       Impact factor: 16.671

10.  Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth.

Authors:  Shingo Ameshima; Heiko Golpon; Carlyne D Cool; Daniel Chan; R William Vandivier; Shyra J Gardai; Marilee Wick; Raphael A Nemenoff; Mark W Geraci; Norbert F Voelkel
Journal:  Circ Res       Date:  2003-04-24       Impact factor: 17.367
View more
  3 in total

1.  Rats with a Human Mutation of NFU1 Develop Pulmonary Hypertension.

Authors:  Maki Niihori; Cody A Eccles; Sergey Kurdyukov; Marina Zemskova; Mathews Valuparampil Varghese; Anna A Stepanova; Alexander Galkin; Ruslan Rafikov; Olga Rafikova
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

2.  Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats.

Authors:  Lu Li; Guanghua Pan; Rong Fan; Dalei Li; Lei Guo; Lili Ma; Hui Liang; Jiaoxue Qiu
Journal:  BMC Complement Med Ther       Date:  2022-07-01

3.  The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.

Authors:  Emma Derrett-Smith; Kristina E N Clark; Xu Shiwen; David J Abraham; Rachel K Hoyles; Olivier Lacombe; Pierre Broqua; Jean Louis Junien; Irena Konstantinova; Voon H Ong; Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2021-09-06       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.